Managing Acoltremon Tolerability and Sustained Tear Production in Dry Eye Disease

In this segment, the expert panel focuses on patient counseling, adherence, and expectation-setting when initiating Acoltremon. The faculty emphasize that despite a high incidence of mild, short-lived burning upon instillation, fewer than 1% of patients discontinued therapy in clinical studies—an outcome they consider remarkable for dry eye trials. The panel explains that transparent communication is essential for maintaining adherence. Expert clinicians describe how they prepare patients by normalizing the initial sensation, framing it as an intentional mechanism of action that activates ocular surface receptors and stimulates natural tear production. They share practical strategies, including advising patients to close their eyes for a minute after instillation or refrigerate the drop to reduce discomfort. The panel also notes that most patients report diminishing sensation over time and often express strong satisfaction once therapeutic benefits emerge. Across the discussion, the experts reinforce that education, reassurance, and expectation management are critical to keeping patients engaged in long-term dry eye treatment.